· Published by Health Canada · Official notice
This is duplicated text of a letter from Apotex Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
August 15, 2014
Dear Healthcare Professional,
Subject: Recall of one lot of APO-MYCOPHENOLIC ACID (DIN: 02372746, Lot # KY6601) due to incorrect tablet strength labelling on the French side panel of the Blister Carton of 360mg pack.
Apotex Inc, in collaboration with Health Canada, would like to inform you that it is recalling one lot (Lot # KY6601) of Apo-Mycophenolic Acid 360 mg tablets. The product is being recalled due to an incorrectly labelled tablet strength on the French side panel of the Blister Carton of the 120 tablet pack, which may pose a risk of potential dosing error. The English version is accurate and identifies the strength correctly as 360 mg tablets. The French side panel incorrectly states 180 mg instead of 360 mg however, the dosage directions in the French statement are correct. The tablet strength indicated on the inner blister packs are correctly labelled, and each tablet is engraved with “MYC 360” on one side.
Apo-Mycophenolic Acid is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids. The recommended adult dose is 720 mg twice a day for a total daily dose of 1440 mg.
Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of dosing error or other serious or unexpected adverse reactions in patients receiving Apo-Mycophenolic Acid tablets should be reported to Apotex Inc. or Health Canada.
Apotex Inc.
150 Signet Drive
Weston, Ontario
M9L 1T9
Phone: 1-800-667-4708
Fax: 1-416-401-3819
Email:Drugsafety@apotex.com
To correct your mailing address or fax number, contact Apotex Inc.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone : 1-800-267-9675
Fax : 1-613-946-5636
Yours sincerely,
Original signed by
Colin D’Cunha MBBS, MHSc, FRCPC
Director, Global Medical Affairs
Apotex Inc.
References:
1 Apo-Mycophenolic Acid Product Monograph. Apotex Inc. 2013.